{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T06:48:44Z","timestamp":1793170124996,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,18]],"date-time":"2019-02-18T00:00:00Z","timestamp":1550448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.vaccine.2019.01.013","type":"journal-article","created":{"date-parts":[[2019,1,18]],"date-time":"2019-01-18T03:52:45Z","timestamp":1547783565000},"page":"1692-1701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8421-8829","authenticated-orcid":false,"given":"Stefan","family":"Scholz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Koerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Meszaros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosa Maya","family":"Fassbender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Ultsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert R.","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Greiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.01.013_b0005","unstructured":"Robert Koch Institute. Invasive meningococcal disease \u2013 cases 2012; 2016."},{"issue":"5","key":"10.1016\/j.vaccine.2019.01.013_b0010","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1473-3099(10)70048-7","article-title":"Global and regional risk of disabling sequelae from bacterial meningitis: a systematic review and meta-analysis","volume":"10","author":"Edmond","year":"2010","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.013_b0015","unstructured":"Robert Koch Institute. SurvStat@RKI 2.0; 2018. Available from: <https:\/\/survstat.rki.de> [cited 2017May25]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0020","unstructured":"Robert Koch Institute. Aktualisierte Stellungnahme der St\u00e4ndigen Impfkommission (STIKO) am Robert Koch-Institut (RKI) [Updated opinion of the Standing Committee on Vaccines at the Robert Koch-Institute]. Epidemiologisches Bull 2018;(3)."},{"key":"10.1016\/j.vaccine.2019.01.013_b0025","series-title":"Annual epidemiological report 2016 \u2013 invasive meningococcal disease","author":"European Centre for Disease Prevention and Control","year":"2016"},{"issue":"9","key":"10.1016\/j.vaccine.2019.01.013_b0030","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1093\/cid\/cir500","article-title":"Comparative long-term adverse effects elicited by invasive group B and C meningococcal infections","volume":"53","author":"Gottfredsson","year":"2011","journal-title":"Clin Inf Dis: Off Publ Inf Dis Soc Am"},{"issue":"9","key":"10.1016\/j.vaccine.2019.01.013_b0035","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S1474-4422(12)70180-1","article-title":"Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study","volume":"11","author":"Viner","year":"2012","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.vaccine.2019.01.013_b0040","first-page":"e20","article-title":"Costs of invasive meningococcal disease: a global systematic review","volume":"32","author":"Wang","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"10.1016\/j.vaccine.2019.01.013_b0045","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s40272-012-0006-0","article-title":"Counting the cost of meningococcal disease, scenarios of severe meningitis and septicemia","volume":"15","author":"Wright","year":"2013","journal-title":"Paediatr Drugs"},{"issue":"9","key":"10.1016\/j.vaccine.2019.01.013_b0050","doi-asserted-by":"crossref","first-page":"869","DOI":"10.2165\/00019053-200624090-00005","article-title":"Cost-of-illness studies, a review of current methods","volume":"24","author":"Akobundu","year":"2006","journal-title":"Pharmacoeconomics"},{"key":"10.1016\/j.vaccine.2019.01.013_b0055","unstructured":"Statistisches Bundesamt [Federal Statistical Office]. Harmonisierter Verbraucherpreisindex [Harmonised consumer price index]; 2018. Available from: <https:\/\/www.destatis.de\/DE\/ZahlenFakten\/GesamtwirtschaftUmwelt\/Preise\/Verbraucherpreisindizes\/Methoden\/harmonisierterVerbraucherpreisindex.html> [cited 2018Apr26]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0060","unstructured":"Institute for Quality and Efficiency in Health Care. Allgemeine Methoden: Entwurf f\u00fcr Version 5.0 vom 07.12.2016 [General method: Draft for version 5.0 from 07.12.2016]; 2016. Available from: <https:\/\/www.iqwig.de\/download\/IQWiG_Methoden_Entwurf-fuer-Version-5_final.pdf> [cited 2017May25]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0065","unstructured":"Statistisches Bundesamt [Federal Statistical Office]. Todesursachenstatistik [Statistic on causes of deaths]. Wiesbaden;2017. Available from: <http:\/\/www.gbe-bund.de\/gbe10\/hrecherche.prc_herkunft_rech?tk=51310&tk2=51311&p_fid=440&p_uid=gast&p_aid=0&p_sprache=D&cnt_ut=1&ut=51311> [cited 2017May25]."},{"issue":"29","key":"10.1016\/j.vaccine.2019.01.013_b0070","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.vaccine.2016.04.004","article-title":"Epidemiological impact and cost-effectiveness of universal vaccination with Bexsero((R)) to reduce meningococcal group B disease in Germany","volume":"34","author":"Christensen","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.013_b0075","unstructured":"Statistisches Bundesamt [Federal Statistical Office]. Krankenhausstatistik, Diagnosedaten der Patienten und Patientinnen in Krankenh\u00e4usern. Diagnosedaten der Krankenh\u00e4user ab 2000 (F\u00e4lle, F\u00e4lle je 100000 Einwohner). Gliederungsmerkmale: Jahre, Wohnsitz, Alter, Geschlecht, Verweildauer, ICD-4-Steller, Art der Standardisierung [Hospital statistic, diagnoses of patients in hospitals. Diagnoses since 2000 (Cases, cases per 100,000 inhabitants). Stratified by: Year, Residence, Age, Sex, Length of stay, ICD-code, Type of standardization]; 2017."},{"key":"10.1016\/j.vaccine.2019.01.013_b0080","unstructured":"Universit\u00e4tsklinikum M\u00fcnster [University hospital Munster]. Webgrouper. Available from: <http:\/\/drg.uni-muenster.de\/index.php?option=com_webgrouper&view=webgrouper&Itemid=107>."},{"key":"10.1016\/j.vaccine.2019.01.013_b0085","unstructured":"Statistisches Bundesamt [Federal Statistical Office]. Krankenhausstatistik, Diagnosedaten der Patienten und Patientinnen in Krankenh\u00e4usern. Diagnosedaten der Vorsorge- oder Rehabilitationseinrichtungen mit mehr als 100 Betten ab 2003 (F\u00e4lle, F\u00e4lle je 100000 Einwohner). Gliederungsmerkmale: Jahre, Wohnsitz, Alter, Geschlecht, Verweildauer, ICD-4-Steller, Art der Standardisierung [Hospital statistic, diagnoses of patients in preventive and rehabilitative institutions. Diagnoses since 2000 (Cases, cases per 100,000 inhabitants). Stratified by: Year, Residence, Age, Sex, Length of stay, ICD-code, Type of standardization];2017."},{"issue":"1","key":"10.1016\/j.vaccine.2019.01.013_b0090","first-page":"53","article-title":"Ermittlung standardisierter Bewertungssatze aus gesellschaftlicher Perspektive fur die gesundheitsokonomische Evaluation [Calculation of standardised unit costs from a societal perspective for health economic evaluation]","volume":"77","author":"Bock","year":"2015","journal-title":"Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany))"},{"key":"10.1016\/j.vaccine.2019.01.013_b0095","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1186\/s12889-015-1693-6","article-title":"Public health management of invasive meningococcal disease in Baden-Wuerttemberg, Germany, 2012, Adherence to guidance and estimation of resources required as determined in a survey of local health authorities","volume":"15","author":"Murajda","year":"2015","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.vaccine.2019.01.013_b0100","unstructured":"Beck E, Meszaros K, Schumacher S, van de Velde N. A sequelae-specific approach to the health economic evaluation of the long-term disease burden of survivors of meningococcal B disease in the UK. London, UK;14.11.2017. (2017 MRF International Conference)."},{"issue":"3","key":"10.1016\/j.vaccine.2019.01.013_b0105","doi-asserted-by":"crossref","DOI":"10.1007\/s00347-009-2036-8","article-title":"Methoden zur Ermittlung pers\u00f6nlicher Krankheitskosten am Beispiel retinaler Erkrankungen [Methods for estimating personal costs of disease using retinal diseases as an example]","volume":"107","author":"Porz","year":"2010","journal-title":"Der Ophthalmologe: Zeitschrift der Deutschen Ophthalmologischen Gesellschaft."},{"issue":"3","key":"10.1016\/j.vaccine.2019.01.013_b0110","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1007\/s00103-012-1624-y","volume":"56","author":"Zeidler","year":"2013","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"issue":"5","key":"10.1016\/j.vaccine.2019.01.013_b0115","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s00103-016-2327-6","volume":"59","author":"Zeidler","year":"2016","journal-title":"Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz"},{"key":"10.1016\/j.vaccine.2019.01.013_b0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jad.2017.01.041","article-title":"Excess costs of social anxiety disorder in Germany","volume":"213","author":"Dams","year":"2017","journal-title":"J Affect Disord"},{"issue":"5","key":"10.1016\/j.vaccine.2019.01.013_b0125","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1097\/00129492-200209000-00013","article-title":"Cost-benefit analysis of pediatric cochlear implantation: German experience","volume":"23","author":"Schulze-Gattermann","year":"2002","journal-title":"Otol Neurotol"},{"issue":"1\u20133","key":"10.1016\/j.vaccine.2019.01.013_b0130","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jad.2012.10.024","article-title":"The cost of depression \u2013 a cost analysis from a large database","volume":"147","author":"Kleine-Budde","year":"2013","journal-title":"J Affect Disord"},{"issue":"12","key":"10.1016\/j.vaccine.2019.01.013_b0135","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1111\/j.1528-1167.2006.00889.x","article-title":"Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany","volume":"47","author":"Hamer","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.vaccine.2019.01.013_b0140","unstructured":"Federal Joint Comittee. Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine Neufassung der Krankenhausbehandlungs-Richtlinie [Resolution of the Federal Joint Comitee on a new version of the inpatient treatment guidline] [22.01.2015]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0145","unstructured":"Deutsche Krankenhausgesellschaft [German Hospital Association]. Gemeinsame Empfehlung \u00fcber die Verg\u00fctung f\u00fcr vor- und nachstation\u00e4re Behandlung nach \u00a7 115 a Abs. 3 SGB V [Consented recommendation on the reimbursement for pre- and post-hospital care, following \u00a7 115 a Abs. 3 SGB V]; [30.10.1996]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0150","first-page":"730891","article-title":"Resource utilisation and costs of depressive patients in Germany: results from the primary care monitoring for depressive patients trial","volume":"2014","author":"Krauth","year":"2014","journal-title":"Depress Res Treat"},{"key":"10.1016\/j.vaccine.2019.01.013_b0155","unstructured":"Spitzenverband Bund der Krankenkassen [Central Federal Association of Health Insurance Funds], Kassen\u00e4rztliche Bundesvereinigung [National Association of Statutory Health Insurance Physicians]. Vereinbarung \u00fcber besondere Ma\u00dfnahmen zur Verbesserung der sozialpsychiatrischen Versorgung von Kindern und Jugendlichen, Sozialpsychiatrie-Vereinbarung. Anlage 11 zu den Bundesmantelvertr\u00e4gen [Agreement about special actions for the improvement of the social-psychiatric care of children and adolescents]. Berlin; [01.07.2009]."},{"issue":"8","key":"10.1016\/j.vaccine.2019.01.013_b0160","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1080\/21645515.2016.1160177","article-title":"Vaccinating Italian infants with a new multicomponent vaccine (Bexsero\u00ae) against meningococcal B disease, a cost-effectiveness analysis","volume":"12","author":"Gasparini","year":"2016","journal-title":"Human Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2019.01.013_b0165","unstructured":"Bundesministerium f\u00fcr Gesundheit [Federal Ministry of Health]. Die Pflegest\u00e4rkungsgesetze, Alle Leistungen zum Nachschlagen [The care strengthening act \u2013 all services]. Berlin: Bundesministerium f\u00fcr Gesundheit;2017."},{"key":"10.1016\/j.vaccine.2019.01.013_b0170","unstructured":"Standing Comittee on Vaccinations (STIKO). Methoden zur Durchf\u00fchrung und Ber\u00fccksichtigung von Modellierungen zur Vorhersage epidemiologischer und gesundheits\u00f6konomischer Effekte von Impfungen f\u00fcr die St\u00e4ndige Impfkommission [Methods for models predicting the epidemiological and health economic effects of vaccinations for the Standing Comittee on Vaccinations], 1st ed. Berlin;[16.03.2016]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0175","unstructured":"Bundesagentur f\u00fcr Arbeit [Federal Labour Office]. Arbeitsmarkt 2015, Arbeitsmarktanalyse f\u00fcr Deutschland, West- und Ostdeutschland [Labor market 2015 \u2013 Analysis of the labor market for Germany, West and East Germany ]. Bundesagentur f\u00fcr Arbeit. N\u00fcrnberg;2016;63(Sondernummer 2)."},{"key":"10.1016\/j.vaccine.2019.01.013_b0180","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1186\/1471-2458-12-968","article-title":"Burden of paediatric influenza in Western Europe: a systematic review","volume":"12","author":"Antonova","year":"2012","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.vaccine.2019.01.013_b0185","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10198-014-0652-y","article-title":"Estimating productivity costs using the friction cost approach in practice: a systematic review","volume":"17","author":"Kigozi","year":"2016","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.vaccine.2019.01.013_b0190","unstructured":"Statistisches Bundesamt [Federal Statistical Office]. Statistik der Geburten [Statistics of births]. Wiesbaden;2017. Available from: <https:\/\/www-genesis.destatis.de\/genesis\/online\/data;jsessionid=00CFF20941E826030ADF1B0983403050.tomcat_GO_1_1?operation=previous&levelindex=4&levelid=1495693859799&levelid=1495693844415&step=3> [cited 2015May25]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0195","unstructured":"Statistisches Bundesamt [Federal Statistical Office]. Sterbetafel: Deutschland, Jahre, Geschlecht, Vollendetes Alter [Life table: Germany, Year, Sex, Age]. Wiesbaden;2017. Available from: <https:\/\/www-genesis.destatis.de\/genesis\/online\/data;jsessionid=F93D601D632270B819625AB4E5CC1EF5.tomcat_GO_2_3> [cited 2017May25]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0200","unstructured":"Statistisches Bundesamt [Federal Statistical Office]. Wirtschaftsrechnungen, Laufende Wirtschaftsrechnungen \u2013 Einkommen, Einnahmen und Ausgaben privater Haushalte 2015 [Economic calculations \u2013 Ongoing economic calculations: Wages, Income and Spenditure of private households];Fachserie 15:Reihe 1. [17.01.2017]."},{"key":"10.1016\/j.vaccine.2019.01.013_b0205","unstructured":"Deutscher Bundestag [German Federal Parliament]. Versorgungsmedizin-Verordnung vom 10. Dezember 2008 (BGBl. I S. 2412), die zuletzt durch Artikel 18 des Gesetzes vom 17. Juli 2017 (BGBl. I S. 2541) ge\u00e4ndert worden ist, VersMedV [Medical Care Regulation]. Available from: <https:\/\/www.gesetze-im-internet.de\/versmedv\/BJNR241200008.html> [10.12.2008]."},{"issue":"5","key":"10.1016\/j.vaccine.2019.01.013_b0210","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1515\/zfsoz-2009-0501","article-title":"Twenty-five years of the german socio-economic panel \u2013 an infrastructure project for empirical social and economic research in Germany","volume":"38","author":"Schupp","year":"2009","journal-title":"Zeitschrift f\u00fcr Soziologie"},{"key":"10.1016\/j.vaccine.2019.01.013_b0215","first-page":"1","article-title":"Multivariate and propensity score matching software with automated balance optimization: the matching package for R","volume":"7","author":"Sekhon","year":"2011","journal-title":"J Stat Softw [Internet]"},{"key":"10.1016\/j.vaccine.2019.01.013_b0220","unstructured":"R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing. Vienna, Austria; 2018. Available from: <https:\/\/www.R-project.org\/>."},{"key":"10.1016\/j.vaccine.2019.01.013_b0225","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/1471-2288-8-22","article-title":"Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies","volume":"8","author":"Lundh","year":"2008","journal-title":"BMC Med Res Method"},{"issue":"6","key":"10.1016\/j.vaccine.2019.01.013_b0230","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/j.jval.2015.05.008","article-title":"Rare disease terminology and definitions \u2013 a systematic global review: report of the ISPOR rare disease special interest group","volume":"18","author":"Richter","year":"2015","journal-title":"Value Health: J Int Soc Pharmacoecon Out Res"},{"issue":"17","key":"10.1016\/j.vaccine.2019.01.013_b0235","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1016\/j.vaccine.2014.01.061","article-title":"Cost-effectiveness of childhood rotavirus vaccination in Germany","volume":"32","author":"Aidelsburger","year":"2014","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.01.013_b0240","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1086\/516716","article-title":"Costs of community-acquired pediatric rotavirus gastroenteritis in 7 European countries: the REVEAL study","volume":"195","author":"Giaquinto","year":"2007","journal-title":"J Infect Dis"},{"issue":"7","key":"10.1016\/j.vaccine.2019.01.013_b0245","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s10198-014-0624-2","article-title":"Recommendation of rotavirus vaccination and herd effect: a budget impact analysis based on German health insurance data","volume":"16","author":"Karmann","year":"2015","journal-title":"Eur J Health Econ: HEPAC: Health Econ Prevent Care"},{"key":"10.1016\/j.vaccine.2019.01.013_b0250","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1186\/s12889-015-1885-0","article-title":"Cost for physician-diagnosed influenza and influenza-like illnesses on primary care level in Germany\u2013results of a database analysis from May 2010 to April 2012","volume":"15","author":"Ehlken","year":"2015","journal-title":"BMC Publ Health"},{"key":"10.1016\/j.vaccine.2019.01.013_b0255","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/S0264-410X(02)00431-0","article-title":"The cost-effectiveness of routine childhood varicella vaccination in Germany","volume":"21","author":"Banz","year":"2003","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19300568?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19300568?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,27]],"date-time":"2019-03-27T18:24:28Z","timestamp":1553711068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19300568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0264410X19300568"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.013","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 GlaxoSmithKline Biologicals SA. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}